

**ASX ANNOUNCEMENT**

9 May 2023

**EZZ Announces Major Distribution Agreement with HIC**

**EZZ Life Science Holdings Limited (ASX: EZZ)** (EZZ or the Company), a genomic life science company with a mission to improve quality of life and human health, is pleased to announce it has entered into a major agreement with Aubay Pty. Ltd. trading as HIC (HIC), for the exclusive distribution rights of two EZZ-branded products (the Agreement). The two-year Agreement forecasts additional annual revenues of at least \$16 million to EZZ commencing from FY24. The Company's full year sales revenue for FY22 was \$15.02 million and more recently EZZ reported sales revenue of \$15.13 million in the half-yearly financial statements to 31 December 2022.

The Agreement between EZZ and HIC is the culmination of several months of negotiations. HIC's social e-commerce model provides a unique opportunity for EZZ products to reach consumers outside of the Company's existing distribution channels, offering significant potential for growth. Market access for EZZ's high-quality Nicotinamide Mononucleotide (NMN) supplement products in China was facilitated when the State Administration for Market Regulation (SAMR) approved NMN as a food additive in February this year.

**Summary Terms of the HIC Agreement:**

- HIC has the exclusive international distribution rights for two EZZ-branded products, excluding Tmall, Douyin and Pinduoduo and all channels in the Australia and New Zealand regions.
- The two EZZ products are;
  - EZZ NMN 175000 Gift Pack; and
  - EZZ L-Lysine Growth Capsule 60.
- Agreed minimum order quantities for both products will result in total annual revenues of at least \$16 million to EZZ.
- Agreement term is 24 months.

**About Aubay**

Aubay Pty. Ltd. is the official Australian entity for HIC, a membership-based, cross-border, social e-commerce platform which has served over three million consumers over the past three years. HIC has a proven track record of working with over 30 reputable international brands to provide premium international products to its members, predominantly based in mainland China but spanning across 27 countries including the UK, Malaysia, USA, and Japan.

**Glenn Cross, Chairman of EZZ Life Science**, commented: *"We are thrilled to have established a new partnership agreement with HIC. HIC's established distribution channels in China and surrounding countries in Asia through its membership-based platform will enable EZZ to expand its reach and market presence. The Company looks forward to a successful partnership with HIC and anticipates the potential for further growth in the coming months."*

*This announcement has been authorised by the Board of EZZ Life Science Holdings Limited.*

**For further information, please contact:**

**Investor Relations**

<https://www.ezzlife.com.au/investors>

[ir@ezzlife.com.au](mailto:ir@ezzlife.com.au)

**About EZZ Life Science**

[EZZ Life Science Holdings Limited \(ASX:EZZ\)](#) is an Australian genomic life science company with a mission to improve quality of life and human health. EZZ Life Science has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. EZZ Life Science is passionate about investing in the future of consumer health through the development of e-commerce and distribution of high-quality products via omnichannel models across Australia, New Zealand, China and worldwide. EZZ Life Science is led by an experienced senior management team that have implemented strategies to drive rapid and ongoing growth of the business.

For more information please visit our corporate site [ezzlife.com.au](https://www.ezzlife.com.au) and our consumer site [ezzdna.com.au](https://www.ezzdna.com.au).